Articles
Volume 9 Supplement 1
Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor
Reviews
Edited by Edward M Schwarz and Christopher T Ritchlin
Supported by an unrestricted grant from Amgen Inc.
|
Biology of RANK, RANKL, and osteoprotegerin Brendan F Boyce, Lianping Xing Arthritis Research & Therapy 2007, 9(Suppl 1):S1 (29 June 2007) |
|
Georg Schett Arthritis Research & Therapy 2007, 9(Suppl 1):S2 (29 June 2007) |
|
Role of RANKL inhibition in osteoporosis Michael McClung Arthritis Research & Therapy 2007, 9(Suppl 1):S3 (29 June 2007) |
|
Multiple myeloma/hypercalcemia Babatunde O Oyajobi Arthritis Research & Therapy 2007, 9(Suppl 1):S4 (29 June 2007) |
|
Mandeep S Virk, Jay R Lieberman Arthritis Research & Therapy 2007, 9(Suppl 1):S5 (29 June 2007) |
|
Yousef Abu-Amer, Isra Darwech, John C Clohisy Arthritis Research & Therapy 2007, 9(Suppl 1):S6 (29 June 2007) |
|
Clinical development of anti-RANKL therapy Edward M Schwarz, Christopher T Ritchlin Arthritis Research & Therapy 2007, 9(Suppl 1):S7 (29 June 2007) |

